Ainos (NASDAQ:AIMD) vs. Centessa Pharmaceuticals (NASDAQ:CNTA) Critical Review

Ainos (NASDAQ:AIMD) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Earnings and Valuation

This table compares Ainos and Centessa Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$20,000.00	474.51	-$14.86 million	($3.98)	-0.50
Centessa Pharmaceuticals	$15.00 million	226.66	-$235.76 million	($1.83)	-13.82

Ainos has higher earnings, but lower revenue than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Ainos and Centessa Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1	0	0	0	1.00
Centessa Pharmaceuticals	1	0	10	2	3.00

Centessa Pharmaceuticals has a consensus target price of $37.70, indicating a potential upside of 49.05%. Given Centessa Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Centessa Pharmaceuticals is more favorable than Ainos.

Insider & Institutional Ownership

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 9.8% of Ainos shares are owned by insiders. Comparatively, 7.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Ainos has a beta of 2.39, indicating that its stock price is 139% more volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Profitability

This table compares Ainos and Centessa Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ainos	N/A	-119.36%	-58.78%
Centessa Pharmaceuticals	N/A	-49.39%	-34.64%

Summary

Centessa Pharmaceuticals beats Ainos on 9 of the 14 factors compared between the two stocks.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.